Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients

被引：20

作者：

Delaugerre, Constance ^{[1
]}

Mathez, Dominique

Peytavin, Gilles

Berthe, Huguette

Long, Kivan

Galperine, Tatiana

de Truchis, Pierre

机构：

[1] Hop Ambroise Pare, APHP, Dept Virol, Boulogne, France

[2] Raymond Poincare Hosp, APHP, Dept Haematol Immunol, Garches, France

[3] Raymond Poincare Hosp, APHP, Dept Infect Dis, Garches, France

[4] Hop Bichat Claude Bernard, APHP, Dept Pharmacol, F-75877 Paris 18, France

来源：

AIDS | 2007年 / 21卷 / 09期

关键词：

D O I：

10.1097/QAD.0b013e32810fd744

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I+I47V, failed on a darunavir/ ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.

引用

页码：1210 / 1213

页数：4

共 12 条

[1] Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors [J].

Barreiro, P ;

Camino, N ;

de Mendoza, C ;

Valer, L ;

Núñez, M ;

Martín-Carbonero, L ;

González-Lahoz, J ;

Soriano, V .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :438-443

[2] TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates [J].

De Meyer, S ;

Azijn, H ;

Surleraux, D ;

Jochmans, D ;

Tahri, A ;

Pauwels, R ;

Wigerinck, P ;

de Béthune, MP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2314-2321

[3]

DEMEYER S, 2006, 13 C RETR OPP INF

[4]

Johnson Victoria A, 2006, Top HIV Med, V14, P125

[5]

KATLAMA C, 2005, 3 IAS C HIV PATH TRE

[6] Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor [J].

King, NM ;

Prabu-Jeyabalan, M ;

Nalivaika, EA ;

Wigerinck, P ;

de Béthune, MP ;

Schiffer, CA .

JOURNAL OF VIROLOGY, 2004, 78 (21) :12012-12021

[7]

LEFEBVRE E, 2006, 46 INT C ANT AG CHEM

[8] Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors [J].

Maguire, M ;

Shortino, D ;

Klein, A ;

Harris, W ;

Manohitharajah, V ;

Tisdale, M ;

Elston, R ;

Yeo, J ;

Randall, S ;

Xu, F ;

Parker, H ;

May, J ;

Snowden, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :731-738

[9]

PICCHIO G, 2006, 46 INT C ANT AG CHEM

[10] Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors [J].

Poveda, Eva ;

Blanco, Francisco ;

Garcia-Gasco, Pilar ;

Alcolea, Antonio ;

Briz, Veronica ;

Soriano, Vincent .

AIDS, 2006, 20 (11) :1558-1560

← 1 2 →